Platinum Investment Management Lt recently announced the acquisition of new stake in Centogene N.V. (NASDAQ:CNTG). The institutional investor has increased its shareholding in the Healthcare company by 4.67% to 2.38 million shares with purchase of 0.11 million shares. This fresh investment now brings its stake to 10.53% valued currently at $2.21 million. In addition, Wells Fargo Clearing Services LLC raised its holdings by 45825.0 to 0.42 million shares. And ACATIS Investment Kapitalverwaltu has lifted its position by 0.19% or 605.0 shares – to 0.32 million shares.
With over 82317.0 Centogene N.V. (CNTG) shares trading Tuesday and a closing price of $1.17 on the day, the dollar volume was approximately $96310.89. The shares have shown a negative half year performance of -26.42% and its price on 01/24/23 gained nearly 15.38%. Currently, there are 22.44M common shares owned by the public and among those 10.13M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for CNTG have a consensus price objective of $2.50. The analysts have set the share’s price value over the next 12 months at a high of $2.50 and a low of $2.50. The average price target is 53.2% above its recent price level and an upside to the estimated low will see the stock gain 53.2% over that period. But an upside of 53.2% will see the stock hit the forecast high price target while median target price for the stock is $2.50.
The top 3 mutual fund holders in Centogene N.V. are Acatis Datini Valueflex Fonds, Platinum Capital Ltd., and Fidelity Nasdaq Composite Index F. Acatis Datini Valueflex Fonds owns 0.32 million shares of the company’s stock, all valued at over $0.3 million. The company bought an additional 605.0 shares recently to bring their total holdings to about 1.41% of the shares outstanding. Platinum Capital Ltd. bought 746.0 shares to see its total holdings expand to 19730.0 shares valued at over $18349.0 and representing 0.09% of the shares outstanding. Fidelity Nasdaq Composite Index F now owns shares totaling to 0.05% of the shares outstanding.
Shares of Centogene N.V. (NASDAQ: CNTG) opened at $1.04, up $0.03 from a prior closing price of $1.01. However, the script later moved the day high at 1.1900, up 15.38%. The company’s stock has a 5-day price change of 13.59% and 17.00% over the past three months. CNTG shares are trading 25.81% year to date (YTD), with the 12-month market performance down to -73.17% lower. It has a 12-month low price of $0.68 and touched a high of $5.18 over the same period. CNTG has an average intraday trading volume of 25.36K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 22.16%, 35.62%, and -34.64% respectively.
Institutional ownership of Centogene N.V. (NASDAQ: CNTG) shares accounts for 66.80% of the company’s 22.44M shares outstanding. Mutual fund holders own 1.56%, while other institutional holders and individual stakeholders account for 13.25% and — respectively.
It has a market capitalization of $27.69M. The earnings-per-share (ttm) stands at -$2.54. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.58% over the week and 7.13% over the month.
Analysts forecast that Centogene N.V. (CNTG) will achieve an EPS of -$0.35 for the current quarter, -$0.35 for the next quarter and $0 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.35 while analysts give the company a high EPS estimate of -$0.35. Comparatively, EPS for the current quarter was -$0.43 a year ago. Earnings per share for the fiscal year are expected to decrease by -104.20%, and 29.10% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Centogene N.V. (CNTG) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the CNTG, a number of firms have released research notes about the stock. Credit Suisse stated their Outperform rating for the stock in a research note on August 05, 2021, with the firm’s price target at $14. Evercore ISI coverage for the Centogene N.V. (CNTG) stock in a research note released on April 24, 2020 offered a In-line rating with a price target of $21. BTIG Research on their part issued Buy rating on December 02, 2019.